Published Date : Nov 28, 2016
ALBANY, NY, Nov 28, 2016 – The report titled “PharmaPoint: Venous Thromboembolism - Global Drug Forecast And Market Analysis To 2025” provides a detailed overview the market for venous thromboembolism (VTE) drugs, including projections for its growth from 2015 to 2025.
The introductory part of the report presents a description of venous thromboembolism, covering aspects such as etiology, pathophysiology, symptoms, diagnosis, and treatment. VTE, which is a blood clot (thrombus) in the deep vein, results primarily in two life-threatening conditions: deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE can occur and re-occur in both non-hospitalized and hospitalized individuals and can result in chronic complications, namely post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). Though most commonly seen in adults and in the elderly, VTE can happen to people in any age group. Young patients afflicted by the malady usually have strong influencing factors, namely leg fractures, multiple trauma, or indwelling central vein lines.
Moving on, the report presents a list of growth drivers in the global VTE drug market. It points out that the relatively new drug called novel oral anticoagulants (NOACs) will be a major factor pushing the growth of the VTE market. NOACs, namely Xarelto, Pradaxa, Savaysa, and Eliquis present doctors with different treatment options, depending upon the patient’s condition. The report makes a comparative reports of the drugs in terms of sales. It also details other forms of drugs such as arixtra (fondaparinux), heparins, and anti-platelets such as aspirin (widely genericized).
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/855951
The report delves into the clinical practices and trends in countries such as France, Italy, the U.S., Germany, Spain, Japan, and the U.K., vis-à-vis VTE. It discusses various unmet needs and opportunities in the market. These include optimal therapy for cancer patients, inadequate prophylaxis in acutely ill patients, best therapy for patients with moderate and severe renal failure, complicated dose adjustments with new oral anticoagulants, etc. The research study also outlines the scope for drug development in the VTE market.
Owing to extensive research and development, many drugs are already being developed and are slated to hit the market sooner or later. The report provides a peek into their clinical trial mapping and the countries that are developing them. It lists betrixaban (betrixaban) and xarelto (rivaroxaban) as the two of the most promising up and coming drugs. Further, the market study talks about other drugs in the pipeline, including anticoagulants, which are at a very early stage of development, and NOACs, which are in the most advanced stage of clinical trials.
Some of the big-ticket companies operating in the industry listed in the report are Boehringer Ingelheim, Janssen (Johnson & Johnson), Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, and Pzifer.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org